DK3773664T3 - Formulering af cyclosporin til anvendelse i behandling af bronchiolitis obliterans syndrom (bos) - Google Patents

Formulering af cyclosporin til anvendelse i behandling af bronchiolitis obliterans syndrom (bos) Download PDF

Info

Publication number
DK3773664T3
DK3773664T3 DK19715929.6T DK19715929T DK3773664T3 DK 3773664 T3 DK3773664 T3 DK 3773664T3 DK 19715929 T DK19715929 T DK 19715929T DK 3773664 T3 DK3773664 T3 DK 3773664T3
Authority
DK
Denmark
Prior art keywords
bos
treatment
bronchiolitis obliterans
obliterans syndrome
cyclosporine formulation
Prior art date
Application number
DK19715929.6T
Other languages
English (en)
Inventor
Oliver Denk
Gerhard Börner
Aldo Iacono
Original Assignee
Breath Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Breath Therapeutics Gmbh filed Critical Breath Therapeutics Gmbh
Application granted granted Critical
Publication of DK3773664T3 publication Critical patent/DK3773664T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK19715929.6T 2018-04-11 2019-04-09 Formulering af cyclosporin til anvendelse i behandling af bronchiolitis obliterans syndrom (bos) DK3773664T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862656226P 2018-04-11 2018-04-11
EP18172067 2018-05-14
PCT/EP2019/058958 WO2019197406A1 (en) 2018-04-11 2019-04-09 Cyclosporine formulations for use in the treatment of bronchiolitis obliterans syndrome (bos)

Publications (1)

Publication Number Publication Date
DK3773664T3 true DK3773664T3 (da) 2024-06-17

Family

ID=66049232

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19715929.6T DK3773664T3 (da) 2018-04-11 2019-04-09 Formulering af cyclosporin til anvendelse i behandling af bronchiolitis obliterans syndrom (bos)

Country Status (14)

Country Link
US (3) US11484566B2 (da)
EP (2) EP4400119A2 (da)
JP (2) JP2021520396A (da)
CN (1) CN112105374A (da)
AU (1) AU2019253137A1 (da)
BR (1) BR112020020564A2 (da)
CA (1) CA3094891A1 (da)
CO (1) CO2020013427A2 (da)
DK (1) DK3773664T3 (da)
FI (1) FI3773664T3 (da)
IL (1) IL277253B2 (da)
LT (1) LT3773664T (da)
MX (1) MX2020010738A (da)
WO (1) WO2019197406A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3069711A1 (en) * 2015-03-16 2016-09-21 PARI Pharma GmbH Cyclosporine formulations for use in the prevention or treatment of pulmonary chronic graft rejection
BR112020020564A2 (pt) * 2018-04-11 2021-01-12 Breath Therapeutics Gmbh Formulações de ciclosporina para uso no tratamento da síndrome de bronquiolite obliterante (bos)
US10736847B2 (en) * 2018-07-03 2020-08-11 Becton, Dickinson And Company Inverting device for liposome preparation by centrifugation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020006901A1 (en) 1999-02-05 2002-01-17 Aldo T. Iacono Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
AU2002350622B2 (en) 2001-10-24 2006-09-14 Pari Pharma Gmbh Kit for the preparation of a pharmaceutical composition
DE102006051512A1 (de) 2005-12-06 2007-06-14 Pari GmbH Spezialisten für effektive Inhalation Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin
EP3069711A1 (en) * 2015-03-16 2016-09-21 PARI Pharma GmbH Cyclosporine formulations for use in the prevention or treatment of pulmonary chronic graft rejection
BR112020020564A2 (pt) * 2018-04-11 2021-01-12 Breath Therapeutics Gmbh Formulações de ciclosporina para uso no tratamento da síndrome de bronquiolite obliterante (bos)

Also Published As

Publication number Publication date
WO2019197406A1 (en) 2019-10-17
EP3773664A1 (en) 2021-02-17
JP2021520396A (ja) 2021-08-19
JP2024069355A (ja) 2024-05-21
IL277253B2 (en) 2024-04-01
MX2020010738A (es) 2020-11-09
US20210077573A1 (en) 2021-03-18
IL277253A (en) 2020-10-29
CO2020013427A2 (es) 2020-11-10
CA3094891A1 (en) 2019-10-17
CN112105374A (zh) 2020-12-18
AU2019253137A1 (en) 2020-11-05
BR112020020564A2 (pt) 2021-01-12
EP4400119A2 (en) 2024-07-17
US11484566B2 (en) 2022-11-01
IL277253B1 (en) 2023-12-01
US11701403B2 (en) 2023-07-18
LT3773664T (lt) 2024-06-10
FI3773664T3 (fi) 2024-07-16
US20230128855A1 (en) 2023-04-27
US20230364182A1 (en) 2023-11-16
EP3773664B1 (en) 2024-05-01

Similar Documents

Publication Publication Date Title
DK3681470T3 (da) Lactobacillus casei eller lactobacillus paracasei til anvendelse i behandling af clostridium difficile-infektioner
DK3490582T3 (da) Sammensætninger til anvendelse i behandling af myelofibrose
DK3889145T3 (da) 8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme
DK3197472T3 (da) Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri
DK3785733T3 (da) Farmaceutisk sammensætning til behandling af autisme
DK3395353T3 (da) Plasminogen til anvendelse til behandling eller forebyggelse af diabetes-mellitus-nerveskade
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3307296T3 (da) Timp2 til anvendelse til behandling af aldringsassocierede tilstande
DK3865484T3 (da) Pde9-hæmmer med imidazopyrazinon-rygrad til behandling af perifere sygdomme
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
DK3773664T3 (da) Formulering af cyclosporin til anvendelse i behandling af bronchiolitis obliterans syndrom (bos)
DK3512506T3 (da) Anvendelse af pridopidin til behandling af retts syndrom
DK3570940T3 (da) Pridopidin til anvendelse i behandling af fragilt x-syndrom
DK3658132T3 (da) Sammensætninger omfattende aminosyrer til anvendelse ved behandling af mitokondrielle dysfunktion-relaterede sygdomme
DK3204038T3 (da) Sammensætninger omfattende amylase til anvendelse i behandlingen af pruritus
DK3609886T3 (da) Benzoazepinanaloger som inhiberingsmidler for bruton-tyrosinkinase
DK3808188T1 (da) Fiskefoder og fremgangsmåde til smoltifikation og forebyggelse af desmoltifikation hos salmonidae samt til profylakse og behandling af hæmoragisk smoltsyndrom (hss) hos salmonidae
DK3522904T3 (da) Flydende sammensætning til anvendelse i behandlingen af gastroesophageal reflux
DK3556383T3 (da) Plasminogen til anvendelse ved behandling af diabetes
DK3666258T3 (da) Fremgangsmåde til behandling af prader-willis syndrom
DK3962601T3 (da) 5-HT2A-agonister til anvendelse til behandling af depression
DK3490625T3 (da) Indretning med struktureret belægning til brug som implantat til behandling af perforeringer i trommehinden
DK3270890T3 (da) Cyclosporin-formuleringer til anvendelse ved forebyggelse eller behandling af kronisk afstødning af lungetransplantat
DK3452100T3 (da) FARMACEUTISKE BÆRERE INDEHOLDENDE miRNAer TIL ANVENDELSE I BEHANDLINGEN AF FIBROTISKE SYGDOMME FORÅRSAGET AF HYPERGLYKÆMI
DK3044229T3 (da) Peptider til anvendelse i behandlingen af oral mucositis